Target to $5 from $12
Friday, May 6, 2022
Citius Pharma to Accelerate Phase 3 Mino-Lok Trial by Expanding Trial Sites
Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that it has selected Biorasi, LLC ("Biorasi"), a global clinical research organization (CRO), to help expand the Company's Phase 3 Mino-Lok trial to additional sites outside the United States. If approved, Mino-Lok would be the first-and-only antibiotic lock solution FDA-approved to salvage infected central venous catheters (CVCs) causing catheter-related blood stream infections (CRBSIs).
https://finance.yahoo.com/news/citius-pharmaceuticals-accelerate-phase-3-133700095.html
Maravai LifeSciences (NASDAQ:MRVI) Given New $40.00 Price Target at Robert W. Baird
Maravai LifeSciences (NASDAQ:MRVI – Get Rating) had its price objective lowered by research analysts at Robert W. Baird from $48.00 to $40.00 in a research report issued on Friday, The Fly reports. Robert W. Baird’s price objective suggests a potential upside of 40.11% from the stock’s previous close.
Insulet (NASDAQ:PODD) Price Target Lowered to $345.00 at Wells Fargo
Insulet (NASDAQ:PODD – Get Rating) had its price target reduced by equities researchers at Wells Fargo & Company from $357.00 to $345.00 in a report released on Friday, The Fly reports. Wells Fargo & Company‘s price target would suggest a potential upside of 52.04% from the company’s current price.
Subscribe to:
Posts (Atom)